Novavax NVAX Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Novavax NVAX

NVAX 8.410

-0.2%

Oct 31 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Glenn Petersen	8/6/2021 4:17:01 AM
	of 166

Novavax delays Covid vaccine emergency authorization submission to FDA until fourth quarter PUBLISHED THU, AUG 5 20214:49 PM EDT UPDATED THU, AUG 5 20216:13 PM EDT Rich Mendez @RICHMENDEZCNBC CNBC.com KEY POINTS -- Novavax announced that it will delay submission of its Covid-19 vaccine to the Food and Drug Administration for emergency use authorization until its fourth quarter. -- Shares of the biotechnology company slipped 10% after the bell. -- The company says it is still on track to produce 100 million doses per month by the end of the third quarter and 150 million per month by the end of the fourth quarter. Novavax announced that it will delay the submission of its Covid-19 vaccine to the Food and Drug Administration for emergency use authorization until its fourth quarter. Shares of the biotechnology company slipped 10% after the bell. The company has filed for regulatory approval in India, Indonesia and the Philippines.P lans to submit the vaccine for emergency use listing at the World Health Organization are set for August, Novavax announced. Approval by the WHO will allow the vaccine to be distributed globally via vaccine sharing initiatives at the global agency. Novavax data from clinical trials indicate that a booster dose of the vaccine candidate provides a 4-fold increase in neutralizing antibody levels after a two-dose regimen of an approved vaccine. The data also indicates that a booster dose of a Novavax vaccine six months after a two-dose regimen of an approved vaccine could provide increased protection against the delta variant and other variants. Despite the delay in U.S. authorization, the company says it is still on track to produce 100 million doses per month by the end of the third quarter and 150 million per month by the end of the fourth quarter. Novavax Covid vaccine: FDA emergency use submission delayed to Q4 (cnbc.com)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next